QLT Inc.
Information about QLT Inc.
Company Name:
QLT Inc.
887 Great Northern Way,
V5T 4T5
Primary Industry:
Pharmaceutical / Drug Development
Researcher, developer, and producer of proprietary pharmaceutical products for the treatment of ocular, oncological, immunological and other diseases. The company's products relate to the field of photodynamic therapy (PDT), a field that uses photosensitizers (light-activated drugs) in the treatment of disease. Visudyne(R), the company's commercial product, has been approved in over 70 countries, including the U.S., Canada and the European Union, for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) in patients with wet age-related macular generation (AMD), the leading cause of severe vision loss in people over the age of 50 in North America and Europe. Visudyne(R) has also been approved in over 50 countries for extended indications, including CNV due to pathologic myopia in the U.S. and the European Union; and CNV due to presumed ocular histoplasmosis syndrome in the U.S.pOther PDT products being developed include verteporfin, an alternative treatment for multiple basal cell carcinoma; and QLT0074, a proprietary photosensitizer for the treatment of benign prostatic hyperplasia (BPH) and androgenetic alopecia (male pattern baldness). The company is also developing non-PDT products, including tariquidar, a treatment for multi-drug resistance in first-line treatment of non-small cell lung cancer. Products are sold to the medical and pharmaceutical industries. The bulk of revenue is derived from activity in the pharmaceuticals industry.
CNV treatment pharmaceuticals - Visudyne(R)